Education
About Us
Working with TipRanks
Follow Us
Immunome (IMNM)
NASDAQ:IMNM
IMNM Stock Chart & Stats
$20.95
-$0.28(-2.60%)
At close: 4:00 PM EST
$20.95
-$0.28(-2.60%)
Day’s Range― - ―
52-Week Range$5.15 - $27.65
Previous CloseN/A
Volume79.27K
Average Volume (3M)1.19M
Market Cap
$2.37B
Enterprise Value$1.20B
Total Cash (Recent Filing)$653.48M
Total Debt (Recent Filing)$3.85M
Price to Earnings (P/E)―
Beta1.67
Next Earnings
May 07, 2026EPS Estimate
-0.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding113,133,200
10 Day Avg. Volume929,464
30 Day Avg. Volume1,191,115
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)2.96
Price to Sales (P/S)270.32
P/FCF Ratio-9.35
Enterprise Value/Market Cap0.51
Enterprise Value/Revenue172.74
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.46
Forecast
1Y Price Target
$35.75Price Target Upside70.64% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
EPS Forecast (FY)-2.52
Revenue Forecast (FY)$9.83M
Bulls Say, Bears Say
Bulls Say
ADC Clinical ProgressAnalyst highlights advancing dose escalation of the ROR1-targeted ADC IM-1021 with multiple patient responses in lymphoma, which could validate the ADC strategy and enable a rapid approval path in select indications.
Commercial OpportunityAnalyst points to a sizable untreated desmoid patient population and management's launch plans across major markets that could translate clinical success into meaningful commercial uptake.
Regulatory FilingAnalyst notes positive Phase 3 results for varegacestat that support a planned New Drug Application submission and the potential for a best-in-class systemic therapy for desmoid tumors.
Bears Say
Cash Burn And Financing RiskAnalyst flags negative operating cash flow and high cash burn that increase the need for future financing and could pressure program timelines.
Clinical Readout UncertaintyAnalyst warns that several key clinical readouts remain pending, creating uncertainty about program outcomes and the timing of potential commercial milestones.
Market SentimentAnalyst notes elevated short interest that signals notable market skepticism and could amplify downside moves if upcoming catalysts disappoint.
Immunome News
IMNM FAQ
What was Immunome’s price range in the past 12 months?
Immunome lowest stock price was $5.15 and its highest was $27.65 in the past 12 months.
What is Immunome’s market cap?
Immunome’s market cap is $2.37B.
When is Immunome’s upcoming earnings report date?
Immunome’s upcoming earnings report date is May 07, 2026 which is in 61 days.
How were Immunome’s earnings last quarter?
Immunome released its earnings results on Mar 03, 2026. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.59 by -$0.17.
Is Immunome overvalued?
According to Wall Street analysts Immunome’s price is currently Undervalued.
Does Immunome pay dividends?
Immunome does not currently pay dividends.
What is Immunome’s EPS estimate?
Immunome’s EPS estimate is -0.55.
How many shares outstanding does Immunome have?
Immunome has 113,133,200 shares outstanding.
What happened to Immunome’s price movement after its last earnings report?
Immunome reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.59. Following the earnings report the stock price went up 4.55%.
Which hedge fund is a major shareholder of Immunome?
Currently, no hedge funds are holding shares in IMNM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Immunome Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$35.75 (70.64% Upside)
$35.75 (70.64% Upside)
Blogger Sentiment
Bullish
IMNM Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 5.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.4%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Very Bullish
Bullish news 93%
Bearish news 7%
Bearish news 7%
Technicals
SMA
Positive
20 days / 200 days
Momentum
125.02%
12-Months-Change
Fundamentals
Return on Equity
-52.09%
Trailing 12-Months
Asset Growth
184.38%
Trailing 12-Months
Company Description
Immunome
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
IMNM Stock 12 Month Forecast
Average Price Target
$35.75
▲(70.64% Upside)
Technical Analysis
Ownership Overview
4.91% Insiders
25.08% Mutual Funds
10.63% Other Institutional Investors
48.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---